Purpose of Review: Head and neck cancers rank as the seventh most common cancer worldwide, nearly half of which result in death. The most common treatment methods for head and neck cancers include radiotherapy and surgery. Proton therapy has emerged in radiotherapy for cases where tumors are located near anatomically sensitive areas where the radiation dose must be strictly limited. The purpose of the work is to discuss the role of the proton therapy in the treatment in various types of cancer, and particularly head and neck tumors. Recent Findings: Proton therapy allows for the delivery of radiation doses to critical organs to be reduced, resulting in a decrease in the occurrence of late adverse effects on these organs. The occurrence of side effects caused by proton therapy depends on the relative and absolute volume of organs at risk receiving specific radiation doses. Summary: Proton therapy represents a promising alternative to conventional radiotherapy due to the reduced number of complications in healthy tissues by delivering a lower radiation dose outside the tumor area.
Polycystic Ovary Syndrome (PCOS), increasingly referred to as polyendocrine metabolic ovarian syndrome (PMOS), is a heterogeneous endocrine–metabolic disorder associated with reproductive dysfunction, hyperandrogenism, insulin resistance, and increased cardiometabolic risk. Due to the central role of insulin resistance, insulin-sensitizing therapies such as myo-inositol (MI), D-chiro-inositol (DCI), and metformin have gained growing clinical attention. Evidence from studies published between 2015 and 2026 suggests that MI and DCI may improve insulin sensitivity, hormonal balance, and reproductive outcomes, including menstrual cycle regularity and ovulation. The 40:1 MI/DCI ratio remains the most extensively studied formulation and appears to reflect physiological proportions. Metformin continues to play a key therapeutic role, particularly in women with insulin resistance, overweight, or obesity, while combination therapy with inositols may provide additional benefits in selected cases. However, evidence remains heterogeneous, highlighting the need for further high-quality randomized controlled trials to clarify the long-term efficacy and optimal clinical use of inositols in PCOS/PMOS management.
Total laryngectomy remains the treatment of choice for advanced stages of laryngeal cancer. Voice prostheses are considered by many authors to be the gold standard for restoring speech after total laryngectomy. Their effectiveness has led to their widespread adoption in clinical practice. As a result, the population of patients using such devices is steadily increasing, which is reflected in a growing scientific interest in this area. This trend has generated an expanding number of studies focused on the analysis of potential complications, available treatment methods in this group of patients. The aim of this review is to analyze potential complications and their management options in patients with tracheoesophageal voice prostheses. All authors independently searched the PubMed database using the following keywords: “tracheoesophageal voice prosthesis,” “primary tracheoesophageal puncture,” “tracheoesophageal fistula,” “laryngectomy,” and “voice prosthesis complications.” Particular attention was paid to reflux therapy with proton pump inhibitors and the potential benefits for patients after laryngectomy. Another important issue discussed in the article concerns methods aimed at reducing biofilm formation on voice prostheses, which consequently translates into longer device lifespan. The effectiveness of botulinum toxin type A was compared with surgical treatment in patients with impaired voice due to spasm of the middle and inferior pharyngeal constrictor muscles (PCM). The studies discussed in this article contribute to improving the quality of life of patients with voice prostheses after laryngectomy. Nevertheless, further research is needed to determine the safety and long-term outcomes of the methods used to manage complications.
The gut microbiota has emerged as an important factor influencing metabolic health of people. Recent research indicates that children with obesity present distinct microbial compositions compared with their normal-weight peers, suggesting a potential role of intestinal microorganisms in the development adiposity. This paper discusses current findings on how dietary patterns, perinatal exposures and inherited microbial traits shape the gut microbiome in childhood. Particular attention is given to taxa associated with metabolic alterations, as well as to microbial metabolites that may influence energy balance and inflammation. Studies linking the gut microbiota to anthropometric measures and early markers of cardiovascular dysfunction highlight its potential value as a diagnostic tool. Understanding these complex host–microbe interactions may contribute to the development of targeted microbiota-based interventions and personalized therapeutic strategies aimed at preventing or treating childhood obesity.
The gut microbiota has emerged as an important factor influencing metabolic health of people. Recent research indicates that children with obesity present distinct microbial compositions compared with their normal-weight peers, suggesting a potential role of intestinal microorganisms in the development adiposity. This paper discusses current findings on how dietary patterns, perinatal exposures and inherited microbial traits shape the gut microbiome in childhood. Particular attention is given to taxa associated with metabolic alterations, as well as to microbial metabolites that may influence energy balance and inflammation. Studies linking the gut microbiota to anthropometric measures and early markers of cardiovascular dysfunction highlight its potential value as a diagnostic tool. Understanding these complex host–microbe interactions may contribute to the development of targeted microbiota-based interventions and personalized therapeutic strategies aimed at preventing or treating childhood obesity.
Sleep disturbances and circadian rhythm disruption in children and adolescents represent a growing public health concern and are increasingly linked to the development of metabolic disorders. Adolescence is characterized by a physiological delay in chronotype which, when combined with social pressures and increasing evening exposure to blue light, promotes desynchronization of the biological clock and the phenomenon of social jetlag. The aim of this paper was to discuss the mechanisms through which circadian rhythm disturbances and sleep deprivation affect glucose metabolism and the risk of insulin resistance in adolescents. Particular attention is given to the role of melatonin and its receptors, activation of the hypothalamic-pituitary-adrenal axis, chronic low-grade inflammation, dysregulation of clock gene expression, alterations in the gut-brain axis, reduced adiponectin levels, and decreased non-exercise activity thermogenesis (NEAT). The significance of chrononutrition and peripheral clock misalignment in the pathogenesis of metabolic jetlag is also addressed. The available evidence indicates that sleep and circadian rhythm disturbances, exacerbated by exposure to blue light, constitute an important and potentially modifiable risk factor for the development of insulin resistance, overweight and obesity during childhood and adolescence.